Europe Diabetes Care Devices Market: By Monitoring Devices (Self-monitoring Blood Glucose Devices, Continuous Glucose Monitoring Devices), By Management Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, Jet Injectors), By Delivery Types (Pumps, Pen, Syringes, Injectors, Cartridges in Reusable pens, Disposable Pens, Jet Injectors), By Distribution Channels (Institutional Sales, Hospitals, Clinics, Others, Retail Sales, Hospital pharmacies, Retail pharmacies, Online pharmacies), and Country

Purchase Option

$ 3100
$ 4600
$ 6900

Europe Diabetes Care Devices Market was valued at USD 7,643.7 million in 2023 and is expected to grow at an 4.4% CAGR from 2024 to 2030. Diabetes care devices are used to monitor diabetics' blood glucose levels. Diabetes care devices are medical devices that track and monitor diabetes patients' blood glucose levels throughout the day. This wearable device will benefit diabetics by assisting them in managing their glucose levels. Moreover, the rise in obesity as well as rising awareness about diabetes management in Europe are the driving factors that drive the growth of the Europe diabetes care devices market. According to the International Diabetes Federation, 21,600 children are added to the type 1 diabetic population pool each year. According to these figures, diabetes accounts for approximately 9% of total healthcare expenditure in Europe. Various government initiatives, such as the National Service Framework (NSF) programme in the United Kingdom, are improving services by establishing national standards to drive up service quality and address variations in care.

However, the glucose testing device is costly and can be painful. Furthermore, the results of diabetes care devices are not always accurate. Factors such as painful sensor insertions and the difficulty of fitting multiple devices on small bodies along with the disruptive alerts lost signals, resulting in data gaps, skin irritation, and adhesive issues impede market expansion. Several government initiatives and awareness campaigns are also driving market growth. The UK DESMOND education programme is a structured patient education and management programme for newly diagnosed type 2 diabetes patients. Its goal is to help people identify early health risks. There has also been an increase in government funding for healthcare.

According to the International Diabetes Federation, diabetes-related healthcare spending is rapidly increasing. Moreover, reimbursement and pricing policies are highly regulated, which drives the market. The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among people are some market opportunities. Further, technological advancements have increased over the period in Diabetes care devices for safer and more accurate administration of insulin. Medtronic launched its first integrated smart insulin pen. The Medtronic Integrated Insulin Pen provides real-time glucose readings of patients along with insulin dose information to manage their glucose levels.

Europe Diabetes Care Devices Market Key Developments:
  • In 2021, Medtronic received a CE mark for its InPen smart insulin pen and Guardian 4 sensor for better diabetes management.
  • In 2021, Medtronic launched the Medtronic Extended infusion set in selected European countries, making it the first and only one that can be worn for up to 7 days.

Europe Diabetes Care Devices Market Dynamics

Obesity is one of the leading causes of diabetes in individuals. Risk factors, such as the rising prevalence of obesity, are directly linked to the rising prevalence of diabetes, resulting in a high diabetes prevalence. As a result, the diabetes device market is growing. Moreover, the increasing diabetes patient pool and rising awareness about diabetes management and control are among the factors expected to contribute to this market's growth over the forecast period. Due to the rising awareness and prevalence of diabetes, the European government has also increased the initiatives regarding the same which is projected to improve the diabetes care devices market in Europe.

Europe Diabetes Care Devices Market Segmentation

By Monitoring Devices
  • Self-monitoring Blood Glucose Devices
  • Continuous Glucose Monitoring Devices
By Management Devices
  • Insulin Pump
  • Insulin Syringes
  • Cartridges in Reusable Pens
  • Insulin Disposable Pens
  • Jet Injectors
By Delivery Type
  • Pumps
  • Pen
  • Syringes
  • Injectors
  • Cartridges in Reusable pens
  • Disposable Pens
  • Jet Injectors
By Distribution Channel
  • Institutional Sales
  • Hospitals
  • Clinics
  • Others
  • Retail Sales
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Frequently Asked Questions

Europe Diabetes Care Devices Market was valued at USD 7,643.7 million in 2023 and is expected to grow at an 4.4% CAGR from 2024 to 2030.

Factors such as painful sensor insertions and the difficulty of fitting multiple devices on small bodies along with the disruptive alerts and lost signals, resulting in data gaps, skin irritation, and adhesive issues are some of the restraint factors that are expected to limit the growth of the Europe diabetes care devices market.

Roche Diabetes Care, Novo Nordisk A/S, Eli Lilly, Sanofi, and Abbott Diabetes Care are some of the major players operating in the Europe diabetes care devices market.

Germany accounts for the largest market share due to the high diabetes prevalence rate and is expected to be the primary market driver in the Europe diabetes care devices market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
  • Roche Diabetes Care
  • Novo Nordisk A/S
  • Eli Lilly
  • Sanofi
  • Abbott Diabetes Care
  • Insulet Corporation
  • Dexcom Inc.
  • Medtronic
  • Agamatrix Inc.
  • Rossmax
  • Ascensia Diabetes Care

Adjacent Markets